anti-tslp news - Search News

Aclaris Therapeutics upgraded to Buy from Hold at Jefferies

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing

YAHOO!Finance · 1h

Aclaris Therapeutics upgraded to Buy from Neutral at BTIG

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb from Chinabased Biosion,

Business Insider · 9h

Aclaris Therapeutics upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120%

Business Insider23h

Promising Potential of Aclaris Therapeutics’ BSI-045B and Pipeline Elevates Buy Rating

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept ...

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Trending now